Induction of early and bioeffective antibody response in rodents with the luteinizing hormone-releasing hormone vaccine given as a single dose in biodegradable microspheres along with alum
✍ Scribed by Diwan, Manish; Dawar, Hema; Talwar, G.P.
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 195 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0270-4137
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
Previous studies in animals and phase i/phase ii clinical trials in humans have shown the suppressive effect of immunization with the luteinizing hormone-releasing hormone (lhrh) vaccine on prostatic hypertrophy and hyperplasia. a drawback of this vaccine was a delay of about 8 weeks in buildup of antibody titers to efficacy level and the requirement of three injections of the vaccine given at monthly interval for full primary immunization.
Methods:
Lhrh vaccine was encapsulated in poly-lactic-co-glycolic acid (plga) 50:50 copolymer microspheres of reproducible physicochemical characteristics. immunogenicity studies were carried out in rodents and prostate weights were determined at various antibody titers.
Results:
The vaccine entrapped in biodegradable microspheres generated high antibody response in rats, persisting for 5-7 months following a single immunization. one hundred micrograms was the optimum dose, and the intramuscular route was more immunogenic than the subcutaneous. it was further observed that coadministration of 75% of the vaccine entrapped in microspheres with 25% adsorbed on alum generated higher antibody response in rodents, exceeding the bioeffective threshold as early as day 15 postimmunization.
Conclusions:
Coadministration of the lhrh vaccine in biodegradable plga microspheres with a quarter of the dose adsorbed on alum generates high antibody titers within 15 days, which are effective in causing atrophy of the prostate.